2020 Annual Meeting | C164 - Clinical Approach to Muscle Disease 2: Inflammatory Myopathies and Muscle Pathology

Date Tuesday 04/28/20

Time 03:30 PM - 05:30 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Tahseen Mozaffar, MD, FAAN

Topic(s) Neuromuscular and Clinical Neurophysiology (EMG)

Learning Objectives Participants should be able to: recognize the various clinical patterns associated with myopathies that will help narrow down the differential diagnosis and judiciously reach a final diagnosis; learn about the role of muscle pathology in diagnosis of inherited and acquired muscle diseases; understand the role of autoimmune myositis associated and myositis specific autoantibodies in managing myositis patients; and understand the various causes of limb-girdle muscular dystrophies and the clinical patterns and role of genetic testing in these disorders. Participants should be familiar with the emerging new therapeutic options in inherited and acquired muscular disorders.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Medical Student

Teaching Styles Case-based, Didactic, Audience Participation

Event Timeline
03:30 PM - 03:40 PM	Introduction	Introductory Remarks Tahseen Mozaffar, MD, FAAN
03:40 PM - 04:35 PM	Speaker	Emerging Therapeutics in Neuromuscular Diseases: Myasthenia Gravis, FSHD, Rare Myopathies Miriam L. Freimer, MD, FAAN
04:35 PM - 05:25 PM	Speaker	Illustrative Muscle Pathology Cases Suur Biliciler, MD
05:25 PM - 05:30 PM	Q&A	Questions and Answers

Faculty Disclosures
Tahseen Mozaffar, MD, FAAN	Dr. Mozaffar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Mozaffar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx. Dr. Mozaffar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Mozaffar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amicus. Dr. Mozaffar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Grifols. Dr. Mozaffar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Astellas Gene Therapy. Dr. Mozaffar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bayer. Dr. Mozaffar has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Mozaffar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Applied Therapeutics. The institution of Dr. Mozaffar has received research support from NIH. The institution of Dr. Mozaffar has received research support from Muscular Dystrophy Association. The institution of Dr. Mozaffar has received research support from Sanofi. The institution of Dr. Mozaffar has received research support from Argenx. The institution of Dr. Mozaffar has received research support from Amicus Therapeutics. The institution of Dr. Mozaffar has received research support from Astellas Gene Therpay. The institution of Dr. Mozaffar has received research support from Cartesian. The institution of Dr. Mozaffar has received research support from Cabaletta. Dr. Mozaffar has received personal compensation in the range of $500-$4,999 for serving as a Study Section Member with NIH.
Miriam L. Freimer, MD, FAAN	Dr. Freimer has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for argenx. Dr. Freimer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for alexion. Dr. Freimer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for J and J. Dr. Freimer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. The institution of Dr. Freimer has received research support from Alnylum. The institution of Dr. Freimer has received research support from UCB. The institution of Dr. Freimer has received research support from NIH. The institution of Dr. Freimer has received research support from Janssen. Dr. Freimer has received research support from Avidity. Dr. Freimer has received research support from Fulcrum. The institution of Dr. Freimer has received research support from Dept of defense. The institution of an immediate family member of Dr. Freimer has received research support from Abcurro. Dr. Freimer has received personal compensation in the range of $10,000-$49,999 for serving as a presentations/teaching with UCB.
Suur Biliciler, MD	Dr. Biliciler has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Efficient CME. Dr. Biliciler has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Argenyx. Dr. Biliciler has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for UCB.

��ɫ��

��ɫ��